Impact of Cannabinoids on Symptoms of Refractory Gastroparesis: A Single-center Experience.

Autor:	Barbash B; Department of Gastroenterology, Bridgeport Hospital, Bridgeport, USA., Mehta D; Department of Gastroenterology and Hepatology, Westchester Medical Center, Valhalla, USA., Siddiqui MT; Digestive Disease and Surgery Institute, Cleveland Clinic, Cleveland, USA., Chawla L; Department of Hospital Medicine, Bridgeport Hospital, Bridgeport, USA., Dworkin B; Division of Gastroenterology and Hepatobiliary Diseases, Westchester Medical Center/New York Medical College, Valhalla, USA.
Jazyk:	angličtina
Zdroj:	Cureus [Cureus] 2019 Dec 20; Vol. 11 (12), pp. e6430. Date of Electronic Publication: 2019 Dec 20.
DOI:	10.7759/cureus.6430
Abstrakt:	Background and aims Cannabinoids are increasingly used for medicinal purposes, including neuropathy. Gastroparesis is a neuromuscular disorder and neuropathy plays a large role in its pathogenesis. It is thus reasonable that cannabinoids can serve a beneficial role in the management of gastroparesis. Our study evaluates the effect of cannabinoids on gastroparesis symptoms. Methods Twenty-four (n=24) patients with gastroparesis and refractory symptoms were selected from a single gastroenterology practice associated with a tertiary care medical center. The 'Gastroparesis Cardinal Symptom Index' (GCSI) and an analog scale rating abdominal pain were applied to prospectively assess the effect of cannabinoids, in the form of dronabinol and medical cannabis, on refractory gastroparesis symptoms. Patients completed a GCSI form and rated their abdominal pain, before and after treatment. There was a minimum of 60 days of cannabinoid use between reporting intervals. Total composite GCSI symptom scores, GCSI symptom subset scores, and abdominal pain scores were calculated before and after treatment. Results A significant improvement in the GCSI total symptom composite score was seen with either cannabinoid treatment (mean score difference of 12.8, 95% confidence interval 10.4-15.2; p-value < 0. 001). Patients prescribed marijuana experienced a statistically significant improvement in every GCSI symptom subgroup. Significant improvement in abdominal pain score was also seen with either cannabinoid treatment (mean score difference of 1.6; p-value <0.001). Conclusions Cannabinoids dramatically improve the symptoms of gastroparesis. Furthermore, an improvement in abdominal pain with cannabinoids represents a breakthrough for gastroparesis-associated abdominal pain treatment, for which there are currently no validated therapies. Competing Interests: The authors have declared that no competing interests exist. (Copyright © 2019, Barbash et al.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu